Engineered exosome for treating gastric cancer as well as preparation method and application of engineered exosome

Through the engineered exosomes loaded with SHMT2 siRNA, the specific binding of CD44 to HA is used to target gastric cancer stem cells, which successfully inhibits the invasion, metastasis and clonal formation capabilities of gastric cancer stem cells, and solves the problem that the existing technology is difficult to effectively target SHMT2. , provides new gastric cancer treatment ideas and shows good biosafety.

CN118879697APending Publication Date: 2024-11-01CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410905120.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-05
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The prior art is difficult to effectively target and inhibit SHMT2 in gastric cancer stem cells, making it difficult to penetrate the tumor stem maintenance mechanism and affect the treatment effect.

Method used

Using engineered exosomes loaded with SHMT2 siRNA, the targeting ability is improved through the specific binding of CD44 to HA. Exosomes derived from gastric cancer cells are loaded with SHMT2 siRNA and combined with HA modification to form HA-Exo-si SHMT2 exosomes. , used to target the treatment of gastric cancer stem cells.

Benefits of technology

HA-Exo-si SHMT2 exosomes significantly inhibit the invasion and metastasis ability of gastric cancer stem cells, cloning formation ability, and reduce the expression of stem markers, providing a new clinical treatment strategy for gastric cancer with good biocompatibility and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879697A_ABST
    Figure CN118879697A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to an engineered exosome for treating gastric cancer as well as a preparation method and application of the engineered exosome. Through multi-omics conjoint analysis and experimental verification, the specific molecular mechanism of the SHMT2 for maintaining the stemness of the gastric cancer stem cells is defined; the stemness characteristic of the GCSC can be maintained by up-regulating the level of serine in the gastric cancer stem cells through high expression of the SHMT2; and the exosome is used for loading SHMT2siRNA to carry out targeted therapy on the gastric cancer. The HA-Exo-si SHMT2 engineered exosome provided by the invention is composed of an exosome derived from gastric cancer cells, SHMT2 siRNA (small interfering Ribonucleic Acid) coated in the exosome and DSPE-PEG2000-HA modified on the surface of the exosome. The engineered exosome can effectively inhibit the stemness characteristics and tumor progression of gastric cancer stem cells in vitro and in vitro, and has good biocompatibility and treatment safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an engineered exosome for treating gastric cancer, and a preparation method and application thereof. Background Art

[0002] Gastric cancer (GC) is one of the most common malignant tumors in the world, ranking third in cancer-related mortality. The incidence of gastric cancer in my country is second only to lung cancer, ranking second among all malignant tumors. Cancer stem cells (CSCs) are a small group of highly heterogeneous cells in tumor tissues that have the ability to initiate tumors, maintain tumor growth, self-renew and reproduce indefinitely, similar to embryonic stem cells. They are also one of the few cell subtypes with stem cell characteristics in tumor tissues. Existing studies have shown that gastric cancer has the characteristics of high metastasis and high recurrence, which may be related to the self-renewal and unlimited reproduction of gastric cancer stem cells. In recent years, more and more research evidence has supported that CSCs are the root cause of tumor initiation, progression, and drug resistance, and the idea of ​​tumor treatment has gradually shifted from the traditional killing of all tumor cells to targeting CSCs.

[0003] CSCs have unique metabolic characteristics and play an important role in the development of cancer. Unlike most tumor cells that mainly rely on glycolysis for energy production, CSCs can switch between different metabolic pathways, including OXPHOS, glycolysis, glutamine metabolism, fatty acid metabolism, etc., according to environmental stimuli and nutrient supply. For example, under normal oxygen conditions, CSCs can produce most of the required ATP from OXOPHOS and fatty acid β-oxidation; under hypoxic conditions, CSCs upregulate glycolysis by enhancing the expression of glycolytic enzymes and GLUTs; glutamine decomposition provides precursors for the biosynthesis of CSCs macromolecules and glutathione; fatty acid metabolism is reprogrammed to maintain the integrity of CSCs cell membranes, etc., which fully reflects the plasticity and flexibility of tumor stem cell metabolism. Therefore, in-depth research on the molecular mechanism of gastric cancer stem cell stemness maintenance and exploration of effective targeted treatment strategies have important theoretical significance and clinical practice value.

[0004] Serine and glycine are the main sources of one-carbon units, and their abnormal metabolism is associated with cancer progression. Previous studies have shown that the inhibition of serine / glycine can effectively induce the accumulation of tumor suppressor lipid metabolites, thereby limiting spheroid formation and tumor growth. SHMT2, as a key enzyme in one-carbon metabolism, regulates the reversible conversion of serine / glycine to produce one-carbon units involved in tumor progression. It not only provides cellular components such as proteins, nucleotides and lipids for tumor proliferation, but also produces glutathione and S-adenosylmethionine to regulate the redox and epigenetic state of cells. In addition, the serine metabolism catalyzed by SHMT2 is essential for maintaining formyl-methionyl-tRNA and initiating proper mitochondrial translation. Studies have shown that SHMT2 is highly expressed in gastrointestinal tumors such as gastric cancer, esophageal cancer, and colorectal cancer, and is associated with cancer progression and poor prognosis, indicating that SHMT2 is a potential diagnostic and therapeutic target for gastrointestinal tumors. Previous studies of the present invention have confirmed that SHMT2 is significantly highly expressed in GCSCs and is potentially involved in maintaining the stemness of tumor stem cells. However, the specific regulatory mechanism by which SHMT2 affects the stemness characteristics of tumor stem cells still needs to be further studied.

[0005] RNA interference (RNAi) has great potential for specific silencing of pathogenic genes, but its clinical application is limited by the development of carrier systems, that is, how to transport siRNA molecules into target cells. Exosomes are important mediators of intercellular communication. Due to their unique biological origin, they have high biocompatibility, high stability and limited immunogenicity. Compared with traditional synthetic delivery carriers, exosomes have multiple advantages as drug delivery systems. Studies have reported that exosomes can be used to deliver siRNA, miRNA, proteins, small molecule drugs, etc. to treat various diseases. Compared with exosomes produced by non-cancerous cells, tumor cell-derived exosomes can achieve tumor cell-specific targeting by utilizing the intrinsic homologous adhesion properties mediated by membrane surface antigens. However, there are currently no patents or articles reporting on si SHMT2 exosomes that can specifically recognize gastric cancer cells and gastric cancer stem cells. Summary of the invention

[0006] In view of this, the present invention deeply explores the role of SHMT2-mediated one-carbon metabolism and lipid metabolism crosstalk in the maintenance of tumor stem cell stemness, and synthesizes exosomes loaded with SHMT2 siRNA to explore targeted treatment of gastric cancer. The present invention found that abnormally highly expressed SHMT2 in gastric cancer participates in the maintenance of GCSCs stemness by regulating one-carbon metabolism (serine / glycine levels) to cause membrane phospholipid remodeling. The HA-Exo-si SHMT2 exosomes provided by the present invention have a good inhibitory effect on the stemness characteristics and malignant biological behaviors of gastric cancer, and the present invention provides a new idea for the clinical treatment strategy of gastric cancer.

[0007] One of the purposes of the present invention is to provide a siRNA for treating gastric cancer.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] The siRNA for treating gastric cancer is SHMT2 siRNA, the nucleotide sequence of the sense chain of the SHMT2 siRNA is shown as SEQ ID NO.1, and the nucleotide sequence of the Antisense chain of the SHMT2 siRNA is shown as SEQ ID NO.2.

[0010] A second object of the present invention is to provide an engineered exosome for treating gastric cancer.

[0011] To achieve the above object, the present invention adopts the following technical solutions:

[0012] Engineered exosomes for treating gastric cancer, the engineered exosomes comprising exosomes and SHMT2 siRNA encapsulated in the exosomes, the nucleotide sequence of the sense chain of the SHMT2 siRNA being shown as SEQ ID NO.1, and the nucleotide sequence of the Antisense chain of the SHMT2 siRNA being shown as SEQ ID NO.2.

[0013] Furthermore, the engineered exosomes also include hyaluronic acid modified on the surface of the exosomes.

[0014] Furthermore, the hyaluronic acid is DSPE-PEG2000-HA.

[0015] The present invention utilizes the specific binding ability of CD44 and HA to further improve the targeting ability of engineered exosomes to tumor stem cells that highly express CD44.

[0016] Furthermore, the exosomes are exosomes derived from gastric cancer cells.

[0017] Furthermore, the average hydrodynamic size of the engineered exosomes was 162.8±9.3 nm.

[0018] Furthermore, the potential of the engineered exosomes was -35.24±2.17 mV.

[0019] After exosomes were loaded with SHMT2 siRNA and HA, the negative potential of the particles was enhanced, which was beneficial for their circulation in the blood.

[0020] Furthermore, the engineered exosomes express characteristic exosomal membrane proteins ALIX and HSP70.

[0021] Exosomes can be used as endogenous nanocarriers to effectively deliver a variety of drug molecules such as nucleic acids, proteins, small molecules and gene therapy agents, and maintain the activity of their contents and achieve efficient targeting. For example, the use of exosomes to deliver siRNA of hepatocyte growth factor HGF can effectively inhibit the growth and angiogenesis of gastric cancer. Tumor cell-derived exosomes can use the intrinsic homologous adhesion properties mediated by membrane surface antigens to achieve tumor cell-specific targeting, and the specific binding ability of CD44 to HA can further improve its targeting ability to tumor stem cells that highly express CD44. In this study, the present invention successfully synthesized HA-Exo-si SHMT2 using exosomes derived from gastric cancer cells to load SHNT2 siRNA and combined with HA modification, and verified its good therapeutic effect and biosafety. Considering the digestive tract environment of gastric cancer and the specific high expression of CD44, the present invention proposes the above-mentioned HA-mExo-si SHMT2 and its preparation method.

[0022] A third object of the present invention is to provide a method for preparing the aforementioned engineered exosomes.

[0023] To achieve the above object, the present invention adopts the following technical solutions:

[0024] The method for preparing engineered exosomes comprises the following steps:

[0025] (1) Gradient ultracentrifugation was used to extract exosomes from gastric cancer cells;

[0026] (2) mixing SHMT2 siRNA with the exosomes obtained in step (1), sonicating, and incubating to obtain exosomes loaded with si SHMT2;

[0027] (3) The si SHMT2-loaded exosomes obtained in step (2) were mixed with DSPE-PEG2000-HA and incubated to obtain HA-Exo-si SHMT2 engineered exosomes.

[0028] Further, in step (1), the gradient ultracentrifugation method comprises:

[0029] 1) Take the cell supernatant, centrifuge at 300g for 10 min, 1500g for 15 min, and 3200g for 20 min, and collect the supernatant;

[0030] 2) centrifuging the supernatant obtained in step 1) at 2000 g for 30 min at 4° C. to collect the supernatant;

[0031] 3) filtering the supernatant obtained in step 2), and then ultracentrifuging at 100,000 g for 70 min at 4° C. to collect exosomes;

[0032] 4) After washing the exosomes obtained in step 3), ultracentrifugation was performed at 100,000 g for 70 min at 4° C., and the precipitate was collected and resuspended to obtain the exosomes.

[0033] Preferably, the purpose of step 2) is to separate exosomes from large vesicles and subcellular structures.

[0034] Preferably, in step 4), washing is performed using sterile 1×PBS (calcium-free, magnesium-free and phenol-free).

[0035] Preferably, in step 4), the resuspending is resuspending in 200ul sterile 1×PBS.

[0036] Furthermore, in step (2), the SHMT2 siRNA is Cy5 fluorescently labeled si SHMT2.

[0037] Furthermore, in step (2), the exosomes and SHMT2 siRNA are mixed in PBS at a mass ratio of 4-6:1, preferably 5:1.

[0038] Furthermore, in the exosomes carrying si SHMT2, the final concentration of the exosomes is 3-6 μg / ml, preferably 4 μg / ml.

[0039] Furthermore, in step (2), the ultrasound was set to an amplitude of 20%, 6 on / off cycles of 30 seconds, and a cooling time of 2 minutes between each cycle.

[0040] Furthermore, in step (2), the incubation is performed at 37±5°C for 60-120 minutes; and / or in step (3), the incubation is performed at 37±5°C for 36-60 hours.

[0041] Preferably, in step (2), the incubation is at 37° C. for 60 minutes to restore the exosome membrane.

[0042] Preferably, in step (3), the incubation is at 37° C. for 48 hours.

[0043] Furthermore, in step (3), after the incubation, low-speed centrifugation is performed to remove excess HA derivatives.

[0044] Preferably, the low speed centrifugation is set to 4000×g.

[0045] A fourth object of the present invention is to provide a use of the aforementioned siRNA and / or the aforementioned engineered exosomes in the preparation of a drug for treating gastric cancer.

[0046] To achieve the above object, the present invention adopts the following technical solutions:

[0047] Use of the aforementioned siRNA and / or the aforementioned engineered exosomes in the preparation of a drug for treating gastric cancer.

[0048] Further, the application includes any one of the following 1)-6):

[0049] 1) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the stemness characteristics of gastric cancer stem cells;

[0050] 2) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the invasion and metastasis ability of gastric cancer cells and / or gastric cancer stem cells;

[0051] 3) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the cloning ability of gastric cancer cells and / or gastric cancer stem cells;

[0052] 4) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the expression of SHMT2, CD44, CD133, KLF4, and c-Myc in gastric cancer cells and / or gastric cancer stem cells;

[0053] 5) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting serine levels in gastric cancer stem cells;

[0054] 6) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for regulating one-carbon metabolism / lipid metabolism.

[0055] Cancer stem cells (CSCs) are a group of heterogeneous cells with stem cell-like properties, which are associated with tumor recurrence, metastasis and treatment resistance, and are the main cause of cancer treatment failure. CSCs play an important role in the development and progression of cancer due to their unique metabolic characteristics. Therefore, in-depth research on the metabolic characteristics of gastric cancer stem cells and their mechanism of action in maintaining stemness is crucial for the diagnosis and treatment of clinical gastric cancer. Targeting the metabolic pathways of CSCs is also expected to become one of the cancer treatment methods.

[0056] In terms of basic research, the present invention proposes that abnormally high expression of SHMT2 in gastric cancer participates in the maintenance of GCSCs stemness by regulating one-carbon metabolism (serine / glycine levels) and causing membrane phospholipid remodeling, providing more sufficient evidence for the flexibility of tumor stem cell metabolism and a new idea for the study of the molecular mechanism of maintaining the stemness of gastric cancer stem cells.

[0057] In terms of technical research, the present invention uses gastric cancer cell-derived exosomes loaded with SHMT2 siRNA and HA to explore targeted treatment of gastric cancer / gastric cancer stem cells. The synthetic engineered exosomes not only have high biocompatibility, stability and limited immunogenicity. At the same time, tumor cell-derived exosomes can utilize the intrinsic homologous adhesion properties mediated by membrane surface antigens and the specific binding of CDD-HA to achieve tumor cell-specific targeting, providing new ideas for the clinical treatment strategy of gastric cancer.

[0058] The beneficial effects of the present invention are:

[0059] 1. The present invention found that SHMT2, a key enzyme in one-carbon metabolism, is significantly overexpressed in gastric cancer and gastric cancer stem cells, and is associated with clinical malignant features and poor prognosis in gastric cancer patients. SHMT2 deficiency in gastric cancer cells leads to downregulation of serine levels, disrupting the maintenance of the stemness of gastric cancer stem cells. The present invention clarifies the specific molecular mechanism of SHMT2 in maintaining the stemness of gastric cancer stem cells through multi-omics combined analysis and experimental verification, which is conducive to the targeted elimination of GCSCs and is of great significance for controlling the occurrence and development of gastric cancer.

[0060] 2. The HA-Exo-si SHMT2 exosomes provided by the present invention have a good inhibitory effect on the stemness characteristics and malignant biological behaviors of gastric cancer in vitro and in vivo, and can effectively inhibit the invasion and metastasis ability, clone formation ability, etc. of gastric cancer cells and gastric cancer stem cells, and significantly reduce the expression of stemness markers c-MYC, CD44, and KLF4 proteins. And the HA-Exo-siSHMT2 exosomes show good gastric cancer targeted therapeutic effects and biosafety. The present invention uses exosomes derived from gastric cancer cells to load SHMT2 siRNA and HA for the first time to explore the targeted treatment of gastric cancer / gastric cancer stem cells, providing a new idea for the clinical treatment strategy of gastric cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 This is the result of ISH detection of SHMT2 expression in gastric cancer tumor tissue and adjacent tissue;

[0062] Figure 2 This is a diagram for statistical analysis of the relationship between SHMT2 ISH score and T, N, and grading and staging, among which, Figure 2 -A is the result of statistical analysis of SHMT2 ISH scores of gastric cancer tumors in stages T1-T2 and T3-T4; Figure 2 -B is the result of statistical analysis of SHMT2 ISH scores of gastric cancer stages N0-N1 and N2-N3; Figure 2 -C is the result of statistical analysis of SHMT2 ISH scores of gastric cancer tumors at stages G1-2 and G2-3; Figure 2-D is the result of statistical analysis of SHMT2 ISH scores of gastric cancer Stage Ⅰ-Ⅱ and Stage Ⅲ-IV;

[0063] Figure 3 -A is the survival prognosis curve of gastric cancer patients grouped by SHMT2 expression. Figure 3 -B is a graph showing the expression of SHMT2 in gastric cancer cells and gastric cancer stem cells;

[0064] Figure 4 -A is a graph showing the correlation between SHMT2 and MYC expression in tumor stem cells in gastric cancer. Figure 4 -B is a graph showing the correlation between SHMT2 and SOX2 expression in tumor stem cells in gastric cancer;

[0065] Figure 5 -A is the IHC staining image of SHMT2 in gastric cancer patients with high and low expression of CD44. Figure 5 -B is a statistical diagram of the IHC scores of SHMT2 in gastric cancer patients with high and low CD44 expression;

[0066] Figure 6 -A is the result of Transwell experiment to detect the changes in the invasion ability of MGC-803 and BGC-823 gastric cancer cells after SHMT2 knockdown. Figure 6 -B is a statistical diagram of Transwell experiment results;

[0067] Figure 7 -A is the result of the change in the clone formation ability of MGC-803 and BGC-823 gastric cancer cells after SHMT2 knockdown. Figure 7 -B is a statistical diagram showing the changes in the clone formation ability of MGC-803 and BGC-823 gastric cancer cells after SHMT2 knockdown;

[0068] Figure 8 This is the result of the gastric cancer stem cell mammosphere formation experiment;

[0069] Fig. 9 -A is the test result of the sphere formation rate of MGC-803 and BGC-823 stem cells after SHMT2 knockdown. Fig. 9 -B is the detection result of MGC-803 and BGC-823 stem cell size after SHMT2 knockdown;

[0070] Fig.10 This is a graph showing the expression of stem cell markers (KLF4, CD44, and c-Myc) after SHMT2 knockdown detected by WB;

[0071] Fig.11This is a picture of subcutaneous tumor formation in gastric cancer cells in mice with SHMT2 knockdown (SHMT#1, SHMT#2) and control group;

[0072] Fig.12 This is the result of amino acid metabolomics detection of changes in serine and glycine content in GCSCs with SHMT2 knockdown and control groups;

[0073] Fig.13 The test results of MGC-803 and BGC-823 stem cells in the control group, SHMT2 knockdown group, and SHMT2 knockdown followed by serine supplementation group;

[0074] Fig.14 -A is the test results of the sphere formation rate of MGC-803 and BGC-823 stem cells in the control group, SHMT2 knockdown group, and SHMT2 knockdown followed by serine supplementation group. Fig.14 -B is the detection result of MGC-803 and BGC-823 stem cell size in the control group, SHMT2 knockdown group, and SHMT2 knockdown followed by serine supplementation group;

[0075] Fig.15 The results of flow cytometry detection of the proportion of CD133+CD44+ gastric cancer stem cells in the control group, SHMT2 knockdown group, and SHMT2 knockdown followed by serine supplementation group;

[0076] Fig.16 The results of WB detection of changes in the expression of gastric cancer stem cell stemness-related proteins (KLF4, CD44, c-Myc) in the control group, SHMT2 knockdown group, and SHMT2 knockdown followed by serine supplementation group;

[0077] Fig.17 Schematic diagram of the synthesis of HA-Exo-si SHMT2;

[0078] Fig.18 The particle size and morphology of HA-Exo-si SHMT2;

[0079] Fig.19 -A is the result diagram of the Zeta potential of HA-Exo-si SHMT2, Fig.19 -B is the seven-day fluid particle size diagram of HA-Exo-si SHMT2, Fig.19 -C is a graph showing the protein expression of HA, ALIX, and HSP70 in extracted exosomes and synthesized HA-Exo-si SHMT2;

[0080] Fig. 20 This is a confocal image showing the co-localization of SHMT2 siRNA and exosomes after PKH67 staining;

[0081] Fig.21 -A is a diagram showing the uptake of HA-Exo-si SHMT2 by gastric cancer and gastric cancer stem cells, Fig.21 -B is a graph showing the uptake of HA-Exo-si SHMT2 by gastric cancer stem cells MGC-803 / GCSC;

[0082] Fig. 22 -A is the result of WB detection of SHMT2 expression in gastric cancer cells and gastric cancer stem cells after HA-Exo-si SHMT2 was taken up; Fig. 22 -B is the result of qRT-PCR detection of SHMT2 expression after MGC-803 and BGC-823 cells took up HA-Exo-si SHMT2;

[0083] Fig.23 This is the result of Transwell experiment to detect the changes in the invasion ability of gastric cancer cells in the untreated group, Exosome-treated group and HA-Exo-si SHMT2-treated group;

[0084] Fig.24 The results of the changes in the clone formation ability of MGC-803 and BGC-823 gastric cancer cells in the untreated group, Exosome-treated group, and HA-Exo-si SHMT2-treated group are shown in the figure;

[0085] Fig.25 The results of the changes in the number and size of gastric cancer cell stem cell spheres in the untreated group, Exosome-treated group, and HA-Exo-si SHMT2-treated group are shown in the figure;

[0086] Fig.26 The results of WB detection of changes in the expression of stem cell markers (KLF4, CD44, c-Myc) in MGC-803 and BGC-823 cells in the untreated group, Exosome-treated group, and HA-Exo-si SHMT2-treated group;

[0087] Fig. 27 -A shows the subcutaneous tumor formation of gastric cancer mice in the HA-Exo-si SHMT2 treatment group and the non-treatment group; Fig. 27 -B is the volume of subcutaneous tumors in gastric cancer mice in the HA-Exo-si SHMT2 treatment group and the non-treatment group;

[0088] Fig.28 The results of the volume changes of gastric cancer mice in the HA-Exo-si SHMT2 treatment group and the non-treatment group are shown in the figure;

[0089] Fig.29This is the result of IHC detection of changes in SHMT2, CD44, c-Myc and KLF4 in subcutaneous tumors of gastric cancer mice in the HA-Exo-si SHMT2 treatment group and the non-treatment group;

[0090] Fig.30 HE staining images of the main organs (heart, liver, spleen, lung, and kidney) in the HA-Exo-si SHMT2 treatment group and the non-treatment group. DETAILED DESCRIPTION

[0091] The technical solution of the present invention will be further described clearly and completely in conjunction with specific embodiments below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present invention.

[0092] In the embodiments of the present invention, the research method and ideas are as follows:

[0093] (1) Immunohistochemistry was used to score gastric cancer tissue microarrays and analyze the relationship between SHMT2 expression and the malignant characteristics and poor prognosis of gastric cancer. Western blotting was used to analyze the expression of SHMT2 in gastric cancer cells and gastric cancer stem cells. Bioinformatics analysis was used to analyze the correlation between SHMT2 expression and the expression of gastric cancer stemness factors MYC and SOX2. Immunohistochemical staining analysis was used to clarify the expression difference of SHMT2 in CD44+ or CD44- gastric cancer tissues. Gastric cancer MGC-803 and BGC-823 cell models with SHMT2 knockdown were constructed, and CCK8, Transwell, clone formation, stem cell sphere formation, infinite dilution, and nude mouse tumor formation experiments were used to verify in vivo and in vitro that SHMT2 is involved in maintaining the stemness of GCSCs and the malignant behavior of gastric cancer.

[0094] (2) SHMT2 was knocked down in GCSCs, and the changes in glycine / serine content in GCSCs were detected by mass spectrometry. Serine was replenished in SHMT2-knocked-down GCSCs, and the changes in the spheroidization ability of GCSCs were detected by stem cell spheroidization assay. The changes in the number of CD133+CD44+ GCSCs were detected by flow cytometry. Western blotting was used to verify the changes in the expression of stemness-related molecules c-Myc, KLF4, and CD44.

[0095] (3) Exosomes from gastric cancer cells were collected by ultra-high-speed gradient centrifugation, and HA-Exo-si SHMT2 was constructed with SHMT2 siRNA and DSPE-PEG2000-HA to explore targeted treatment of gastric cancer. Transmission electron microscopy was used to observe the morphology of exosomes, nanoparticle tracking analysis (NTA) was used to analyze the particle size and potential of exosomes, and WB was used to analyze the expression of exosome markers (ALIX, HSP70, etc.) and loaded HA. Laser confocal microscopy was used to detect the co-localization of SHMT2 siRNA and exosomes, as well as the uptake of HA-Exo-si SHMT2 by gastric cancer cells and gastric cancer stem cells. qRT-PCR and Western blotting were used to detect the knockdown of SHMT2 in gastric cancer cells after HA-Exo-si SHMT2 uptake. CCK8, Transwell, clone formation and stem cell sphere experiments were used to verify the in vitro therapeutic effect of HA-Exo-si SHMT2 on gastric cancer cells, and HA-Exo-si SHMT2 was injected into nude mice to verify its in vivo therapeutic effect. HE staining of various organs and blood routine analysis were performed to determine the biosafety of HA-Exo-si SHMT2.

[0096] In the embodiment of the present invention, the material information is as follows:

[0097] 1. Tissue Samples

[0098] Pathological tissue sections (cancer tissue and adjacent paracancerous tissue) of gastric cancer patients were obtained from Chongqing Medical University, and gastric cancer tissue chips were purchased from Shanghai Aowei Biotechnology.

[0099] 2. Cell lines and plasmids

[0100] Normal gastric epithelial cells GES-1 and gastric cancer cell lines MGC-803 and BGC-823 were donated by Professor Yang Ke from Beijing Institute of Oncology; retroviral plasmid pBABE-puro, lentiviral plasmid pLVX-puro and competent Escherichia coli DH5α were preserved by the Key Laboratory of Clinical Laboratory Diagnosis of Ministry of Education, Chongqing Medical University; SHMT2 knockdown and overexpression viruses were purchased from Shanghai Jima Company; Cy5-si SHMT2 was purchased from Qingke Biotechnology Co., Ltd.

[0101] 3. Experimental Animals

[0102] Nude mice (BALB / cA-nu, 4 weeks) were purchased from Chongqing Tengxin Biotechnology Co., Ltd.

[0103] In the embodiment of the present invention, the main reagents and consumables are shown in Table 1.

[0104] Table 1. Main reagents and consumables

[0105]

[0106] In the embodiment of the present invention, the main instruments are shown in Table 2.

[0107] Table 2. Instrument information table

[0108]

[0109]

[0110] In the embodiments of the present invention, the main reagents and solution preparation methods are as follows:

[0111] Cell culture medium (DMEM / 1640): In a sterile cell clean bench, add 50 mL of fetal bovine serum (FBS) to 500 mL of DMEM medium or 1640 medium bottle to prepare a cell culture medium containing 10% FBS. Take out the 100 mL serum bottle after autoclaving, distribute the assembled cell culture medium, seal and label it, and store it in a 4°C refrigerator. If necessary, add 1 mL of penicillin-streptomycin solution to the vial to prevent bacterial contamination (content is 1%).

[0112] Cryopreservation solution: Sterilize the glass centrifuge tubes with caps or directly purchase several 15 mL sterile plastic centrifuge tubes. In a sterile cell operation table, add 9 mL of fetal bovine serum (FBS) and 1 mL of DMSO to each tube. Seal the tubes aseptically and mark them. Store them in a -20°C refrigerator and use them promptly.

[0113] Phosphate saline (PBS) buffer: Use a measuring cylinder to measure 2000 mL of double distilled water and add it to a glass container. Then pour in PBS dry powder (2 L) to prepare 2 L PBS solution. Use a magnetic stirrer to fully stir and dissolve, then dispense into small glass bottles, sterilize under high pressure, seal and label, and store at room temperature between cells.

[0114] Pancreatic enzyme digestion solution: Weigh appropriate amount of pancreatic enzyme powder and EDTA into a beaker, add autoclaved PBS and stir to dissolve, and prepare pancreatic enzyme digestion solution (ratio: 0.25% pancreatic enzyme, 0.02% EDTA). In a sterile cell operation table, filter the prepared pancreatic enzyme solution with a 0.22μm microporous filter and dispense into 100mL sterile serum bottles, seal and label, and store at -20℃.

[0115] 0.5% crystal violet stain solution: dilute the purchased crystal violet stain solution with PBS solution to 0.5% crystal violet stain solution, then filter it with filter paper and seal it for use.

[0116] LB liquid culture medium: Weigh a certain proportion of tryptone (1%), yeast extract (0.5%), and NaCl (1%) into a glass bottle, add a certain amount of double distilled water, and adjust to a suitable pH value. After high-pressure sterilization, seal the bottle and store it at 4°C.

[0117] LB solid culture medium plate: Add an appropriate amount of double distilled water to a glass container, and weigh 5g of tryptone, 10g of yeast extract, 10g of NaCl, and 5g of agar powder into the container, adjust to a suitable pH value, and finally adjust the volume to 1L. If antibacterial effect is required, add 100mg / mL of ampicillin (Amp). After the liquid culture medium is cooled to room temperature after high pressure, pour it into a round culture dish and let it stand. After cooling, inoculate it as soon as possible.

[0118] In the embodiment of the present invention, the cell culture method is as follows:

[0119] Gastric cancer MGC-803 cell line was cultured in DMEM medium (containing 10% FBS). Gastric normal epithelial cells GES-1 gastric cancer BGC-823 and BGC-823 / Drosha KD cells were cultured in 1640 medium (containing 10% FBS). The cells were placed in an incubator (culture conditions: 37°C, 5% CO 2 ) growth, when the cells are in good condition and the density reaches 80%-90%, discard the supernatant and add trypsin to digest the cells for passaging or freezing.

[0120] In the embodiment of the present invention, the method for constructing a stable cell model of SHMT2 overexpression and knockdown is as follows:

[0121] After digestion with trypsin, the gastric cancer cells in each group were counted and 1×10 5 Gastric cancer cells were inoculated in 6-well plates as described above. After the cells adhered to the wall, the culture medium was replaced. The cell growth status was observed, and 6 μg / mL of polybrene and a certain amount of virus (calculated according to MOI) were added for culture. After 24 hours, the virus transfection efficiency was observed under a fluorescence microscope, and the serum culture medium was replaced in time. After 72 hours, 2 μg / mL of puromycin was added for screening for 7 days, and then the dose was halved for screening for 7 days. After screening, a stable knockdown or overexpression cell model was obtained. After the screening, the cells were collected, and the expression level of the target gene was verified by qRT-PCR and Western Blot to determine whether the cell model was successfully constructed.

[0122] In the embodiment of the present invention, the real-time fluorescence quantitative PCR analysis (qRT-PCR) method is as follows:

[0123] 1. Primer design and synthesis

[0124] The primer sequences were designed and synthesized by Shanghai Bioengineering Co., Ltd. The primer sequences are shown in Table 3.

[0125] Table 3. Primer sequence list

[0126]

[0127]

[0128] 2. Extraction of total cellular RNA

[0129] (1) When the cell density reaches 80%-90%, remove the 6-well plate, discard the culture medium, wash three times with pre-cooled PBS, and place on ice for subsequent steps;

[0130] (2) Use an enzyme-free pipette tip to pipette 1 mL of pre-cooled Trizol into each well of a six-well plate, place in a refrigerator for 10 min, then repeatedly pipette the cells in the well with a pipette gun and pipette into a 1.5 mL enzyme-free EP tube;

[0131] (3) Use a non-enzyme pipette to draw 0.2 mL of chloroform into the tube for extraction, shake thoroughly on a shaker for 1 min, let stand on ice for 10 min, and centrifuge at 12,000 rpm for 15 min in a precooled 4°C centrifuge;

[0132] (4) Use a pipette tip without enzyme to absorb 0.4 mL of the transparent colorless supernatant (be careful not to absorb the white precipitate), place it in another EP tube without enzyme, add an equal amount of isopropanol, shake thoroughly, place on ice for 10 min, and repeat the above centrifugation at 12,000 rpm for 15 min.

[0133] (5) After discarding the supernatant, a precipitate was visible at the bottom. Ethanol (75%) was added to wash the precipitate. Centrifugation was performed at 12,000 rpm for 5 min and the supernatant was discarded. This step was repeated twice.

[0134] (6) Incubate at 7500 rpm for 2 min, carefully aspirate the supernatant, and open the EP tube cap to allow the residual alcohol to evaporate for 8-10 min;

[0135] (7) Add a certain amount of DEPC water to dissolve the precipitate, gently shake to mix, and detect the RNA concentration.

[0136] 3. Reverse transcription to cDNA

[0137] Reverse transcription is a two-step process:

[0138] (1) Removal of genomic DNA. The reaction system is shown in Table 4.

[0139] Table 4. Reaction system for removing genomic DNA

[0140]

[0141] (2) The cDNA reverse transcription synthesis reaction system is shown in Table 5.

[0142] Table 5. cDNA reverse transcription synthesis reaction system

[0143]

[0144] 4. Fluorescence quantitative PCR amplification

[0145] Reagents were added according to the reaction system in Table 6, and 3 replicate wells were set for each sample.

[0146] Table 6. Reaction system for fluorescence quantitative PCR amplification

[0147] SYBR premix Ex TaqⅡ 15μL Forward primer 1.2μL Reverse primer 1.2μL Reverse transcription cDNA 3μL <![CDATA[ddH 2 O(High-pressure packaging)]]> up to 30μL

[0148] Reaction procedure: 94℃ for 30s, 95℃ for 20s, set the corresponding annealing temperature according to the primer Tm value, react for 30s, 72℃ for 20s, 39 cycles. The miRNA internal reference is U6, the gene internal reference is β-actin or GAPDH, and the relative expression of the gene is obtained by calculating the ct value.

[0149] In the embodiment of the present invention, the Mammosphere culture method is as follows:

[0150] (1) Cell digestion: Select cells that are in the logarithmic growth phase and in good growth condition, and gently wash the cells three times with PBS. Use 0.25% trypsin solution to digest the cells. After digestion, add 1 mL of complete culture medium to terminate the reaction, and transfer the cell suspension to a centrifuge tube. After centrifugation (500 rpm, 5 min), gently discard the supernatant. Resuspend the cell pellet into a single cell suspension with an appropriate amount of tumor stem cell culture medium, and then count the cells.

[0151] (2) First generation mammosphere culture: A 6-well plate coated with 1.2% Poly-HEMA was used to culture mammospheres. 2 ml of cancer stem cell culture medium (containing 1×10 4 After gently shaking to mix, place in a cell culture incubator and culture under normoxic or hypoxic conditions for 7 days. The cell status should be observed regularly.

[0152] (3) Second generation culture of microspheres: Collect the cell suspension into an EP tube, centrifuge at 400rpm for 5min, discard the supernatant, wash the cells twice with PBS, add 200μL 0.25% trypsin to digest the cells, and gently blow to disperse the cells. Add tumor stem cell culture medium to resuspend the cells, blow and mix well, and then count the cells. Inoculate the cells into a new 6-well plate coated with 1.2% Poly-HEMA, add CSCs culture medium (containing 1×104 cells per ml), shake gently to mix, and place in a cell culture incubator for 7 days.

[0153] (4) Photography under a microscope: Observe the state of each group of mammospheres under a microscope and take photos.

[0154] (5) Result analysis: Count the number of mammospheres in each group and measure the diameter of each mammosphere. Calculate the spheroidization rate of each group based on the number of mammospheres and the number of original cultured cells. Statistical results are obtained and a final spheroidization efficiency result graph is plotted.

[0155] In the embodiment of the present invention, the clone formation experimental method is as follows:

[0156] (1) Digestion of cells: The cell status of each group was observed under a microscope, and cells in the logarithmic growth phase and in good growth status were selected. The cells were digested with 0.25% trypsin, and the digested cells were prepared into a single cell suspension.

[0157] (2) Seed plate: 3×10 3 Resuspend the cells in 3 mL of culture medium, mix by pipetting, and evenly seed 3 mL of cell suspension into three duplicate wells of a 6-well plate. Add 1 ml of culture medium to each well, gently rotate to evenly disperse the cells, and culture the cells under normoxic or hypoxic conditions.

[0158] (3) Fixation: After the cell clones grow to the ideal state (10-14 days), the culture is terminated. After careful washing with PBS solution twice, methanol is added to fix at room temperature for 20 minutes, and then washed twice with PBS.

[0159] (4) Staining: After washing away the residual methanol fixative, add 0.5% crystal violet staining solution, stain for 5-15 minutes, rinse with ddH2O, and air dry. Observe the results under a microscope and take photos, and calculate the clone formation rate of each group.

[0160] In the embodiment of the present invention, the Western Blot experimental method is as follows:

[0161] 1. Protein Extraction

[0162] (1) Collecting cells: Treat the cells in advance according to the experimental requirements. After the treatment, confirm that the cells are in good condition, add pre-cooled PBS to wash, repeat 3 times, scrape the cells and collect them into a 1.5 mL EP tube, and centrifuge.

[0163] (2) Cell lysis: After removing the supernatant as much as possible, add an appropriate amount of RIPA protein lysis buffer containing 1% PMSF according to the size of the precipitate, and lyse on ice for 30 minutes, vortexing 5-6 times during the period, each time for 1 minute. After the lysis is completed, ultrasonic lysis on ice for 5-10 seconds; centrifuge (4°C, 12000 rpm, 30 minutes), and collect the supernatant into a new EP tube.

[0164] (3) Protein concentration determination: The BCA method was used to detect the protein sample concentration. The operation was as follows:

[0165] a. Prepare eight protein standard samples with a continuous concentration gradient according to the instructions (the concentrations are 0 μg / μl, 0.025 μg / μl, 0.05 μg / μl, 0.1 μg / μl, 0.2 μg / μl, 0.3 μg / μl, and 0.4 μg / μl, respectively).

[0166] b. Dilute 2 μl of the protein sample to be tested ten-fold with PBS and add it to the sample wells for labeling.

[0167] c. Prepare BCA working solution (Solution A: Solution B = 50:1), mix thoroughly, add 200 μl of working solution to each well, and incubate in a 37°C water bath for 30 min.

[0168] d. Use an ELISA instrument to measure the OD value of each sample well at 570 nm, draw a standard curve based on the corresponding relationship between the concentration of the standard and the OD value, and calculate the concentration of the sample to be tested based on the standard curve using the OD value of the sample to be tested.

[0169] e. Boiling water bath: Add 5× Loading Buffer (protein solution: loading buffer = 4:1) to the collected protein supernatant, place the prepared protein solution at 95-100°C for 8 min, and store the sample in a -40°C refrigerator after cooling (divide in advance to avoid repeated freezing and thawing).

[0170] 2. SDS-PAGE protein electrophoresis

[0171] (1) Gel preparation: According to the molecular weight of the target protein, select the appropriate concentration of separation gel and stacking gel preparation scheme. After confirming that the stacking gel is solidified, add SDS electrophoresis buffer to cover all sample wells.

[0172] (2) Loading: Add protein markers at both ends and add protein samples in sequence.

[0173] (3) Electrophoresis: The electrophoresis was performed in a two-step method and constant voltage mode. 80 V, 30 min → 120 V, 60-90 min (electrophoresis time was based on the time when the marker reached the molecular weight of the target protein).

[0174] (4) Activation of PVDF membrane: Soak the labeled PVDF membrane in methanol solution for 30 seconds and activate it with ddH 2 After washing with 0.05% O for 2 minutes, store in wet transfer solution.

[0175] (5) Transfer: After electrophoresis, cut the gel according to the molecular weight of the protein marker; place and clamp the transfer clamp in a "sandwich structure" in the order from positive to negative: sponge, filter paper, PVDF membrane, target gel strip, filter paper, sponge; transfer the membrane in an ice bath under constant current mode (210mA), and the transfer time is determined according to the molecular weight of the protein to be detected.

[0176] (6) Blocking: When the transfer time is reached, use tweezers to clamp the PVDF membrane into 1×TBST and rinse it once. Use filter paper to absorb the surface moisture, add 5% skim milk powder, and block it at room temperature for 2 h.

[0177] (7) Incubation with primary antibody: After the blocking time is reached, remove the PVDF membrane with tweezers, wash it with 1× TBST, absorb the liquid on the surface of the PVDF membrane with filter paper, and then immerse it in the diluted primary antibody of interest and incubate it on a shaker at 4°C for 16-18 h.

[0178] (8) Incubation with secondary antibody: After the primary antibody incubation is completed, the primary antibody is recovered and the PVDF is washed three times with 1×TBST on a shaker, each time for 10 min. After the residual liquid on the surface is dried, HRP-labeled goat anti-rabbit / mouse secondary antibody is added to the surface of the PVDF membrane, placed on a clean wax plate, and incubated at room temperature for 1 h.

[0179] (9) Chemiluminescence: PVDF was washed three times with 1× TBST on a shaker for 15 min each time. After absorbing the residual liquid on the surface of the PVDF membrane, freshly prepared ECL luminescent solution was applied to the surface of the PVDF membrane (covering the entire PVDF membrane) under light-proof conditions and scanned with a gel imaging analyzer.

[0180] In the embodiment of the present invention, the RNA-seq method is as follows:

[0181] The specific process of high-throughput sequencing includes: extracting total RNA from cells treated with hypoxia / normoxia in an RNase-free environment; using specific probes to remove ribosomal RNA from RNA products and further purifying them; breaking RNA into fragments and using SMARTer TM The PCR cDNA Synthesis Kit reverse transcribed mRNA into cDNA, and then amplified the cDNA. The cDNA fragments were further screened to obtain a sequencing library. The library was sequenced using the PacBio Sequel sequencing platform, and the data were analyzed to obtain differentially expressed genes between the groups.

[0182] In the embodiment of the present invention, the nude mouse tumor formation experimental method is as follows:

[0183] The mammospheres of each group of cells treated with hypoxia or normoxia were configured as 1×10 5 , 1×10 4 , 1×10 3Single cell suspension was prepared and resuspended in 100 μl PBS for later use. The cell suspension was subcutaneously injected into the mammary fat pad of female nude mice, with 7 nude mice in each group. The tumor volume was recorded every two days, and the tumor growth curve was recorded. After the experiment, the animals were killed with 2% sodium pentobarbital anesthetic plus high concentration of carbon dioxide, the tumor tissue was peeled off, photos were taken, and the tumor volume and weight were recorded. The number of tumors in each group was counted, and the tumor formation rate and stem cell ratio of each group were calculated according to ELDA.

[0184] In the embodiment of the present invention, the HE (hematoxylin-eosin) staining method is as follows:

[0185] (1) The lung and liver tissues obtained from the nude mouse liver-lung metastasis experiment were sent to Sevier for paraffin embedding.

[0186] (2) Fix the paraffin on the microtome, insert the blade to make continuous paraffin sections, place the sections in a water bath nearby to float, then spread them on glass slides and dry them.

[0187] (3) Place the desired white sheet in an oven at 80°C for 1-2 hours, and then place it in glass containers containing xylene I, xylene II, and xylene III in sequence, and let it stand for 10 minutes each time.

[0188] (4) Remove the slices from xylene and place them in a gradient of alcohol for dehydration, i.e., place them in anhydrous ethanol I, anhydrous ethanol II, 95%, 75%, and 50% alcohol cylinders in sequence, leaving them for 5 min each time, and finally rinse them with double distilled water.

[0189] (5) Add the purchased hematoxylin to the slide tissue, then rinse the remaining stain with tap water and observe under a microscope to see if the staining is appropriate.

[0190] (6) Add the purchased eosin stain solution, rinse and observe the staining status under the microscope.

[0191] (7) The stained sections were placed in 95% alcohol, anhydrous ethanol I, and anhydrous ethanol II in sequence for gradient dehydration, with each step lasting 2 min. The sections were then soaked in xylene I and xylene II for 2 min, dried at room temperature, and sealed with a neutral resin.

[0192] (8) Microscope observation: Observe the heart, liver, spleen, lungs, and kidneys under a microscope and take photos.

[0193] In the embodiment of the present invention, the immunohistochemical staining IHC method is as follows:

[0194] (1) Dewaxing: Bake the paraffin sections at 80°C for 2 h and then soak them in xylene for 30 min.

[0195] (2) Gradient dehydration: Alcohol gradient dehydration (100%-95%-75%-50%, five minutes each).

[0196] (3) Rinse gently with running water for 5 minutes, taking care to avoid direct impact on the slide.

[0197] (4) Antigen retrieval: Soak the tissue sections completely in citrate buffer solution, boil under high pressure for 30 min, cool naturally to room temperature, and then wash with PBS for 3 times with oscillation, 2 min each time.

[0198] (5) Block endogenous peroxidase: Add enough 3% HO to completely cover the tissue. 2 O 2 Solution, incubate at 37°C for 10 min, and wash with PBS three times, 2 min each time.

[0199] (6) Primary antibody binding: Shake dry without washing, add primary antibody dilution solution that can completely cover the tissue, and incubate at 4°C for 12-16 hours.

[0200] (7) Reaction enhancement: add appropriate amount of reaction enhancement solution, incubate at 37°C for 20 min, and then wash three times with PBS, 2 min each time.

[0201] (8) Secondary antibody binding: After drying the remaining PBS on the slices, add an enhanced enzyme goat anti-mouse / rabbit IgG that can completely cover the tissue. Incubate at 37°C for 20 min and then wash with PBS three times, 3 min each time.

[0202] (9) DBA color development: Shake off the PBS on the tissue, add freshly prepared DAB color developer, observe the color change of the tissue under a microscope, and immediately soak in tap water to stop the color development.

[0203] (10) Restaining: Add hematoxylin to dye the cell nucleus blue (staining time is about 30 seconds), rinse with tap water to terminate staining, and let it dry naturally.

[0204] (11) Sealing: Dehydrate the tissue sections with graded alcohol, make them transparent in xylene, and seal them with neutral resin. Observe the results under a microscope and take photos.

[0205] In the embodiment of the present invention, the metabolic detection method is as follows:

[0206] (1) Sample collection: Collect cells from each group (approximately 7 million per sample), count them, keep the cell pellet, and quickly freeze them in liquid nitrogen. The collected samples are then sent to the company on dry ice for lipid metabolomics testing.

[0207] (2) Metabolic detection: Metabolic detection (LC / MS-MS) was performed by Shanghai Aqu Biotechnology Co., Ltd.

[0208] In the embodiment of the present invention, the immunofluorescence (IF) experimental method is as follows:

[0209] (1) A 24-well plate is covered with a 14 mm slide and cells are inoculated to allow the cells to grow on the slide.

[0210] (2) The cells were washed three times with PBS and then fixed with 4% paraformaldehyde for 15 min.

[0211] (3) Wash with PBS three times and permeabilize the membrane with 0.1% Triton for 15 min.

[0212] (4) Wash three times with PBS and block with goat serum for 30 min. Then aspirate the blocking solution without rinsing.

[0213] (5) Add primary antibody diluted in goat serum (1:200), 200 μl per well, and incubate overnight at 4°C.

[0214] (6) Wash with PBS three times, 5 min each time, add diluted fluorescent-labeled secondary antibody and incubate at room temperature for 1 h.

[0215] (7) Wash with PBS three times, 5 min each time, and protect from light.

[0216] (8) Counterstain the cell nucleus with DAPI for 5 min in a dark environment.

[0217] (9) Wash with PBS three times, 5 min each time, and seal the slides and take photos under a microscope.

[0218] In the embodiment of the present invention, the physical and chemical properties of HA-Exo-si SHMT2 were detected by transmission electron microscopy to observe the morphology of exosomes, nanoparticle tracking analysis (NTA) to analyze the particle size of exosomes, and a potential analyzer to measure its Zeta potential. WB analyzed the expression of exosome markers (ALIX, HSP70, etc.) and HA. PKH67 staining and flow cytometry confirmed the uptake of HA-Exo-si SHMT2 by gastric cancer cells and GCSC.

[0219] In the embodiment of the present invention, the statistical analysis was performed using the statistical software SPSS22.0. The numerical results are shown as mean ± standard deviation. The variance test was used for multi-group sample analysis, followed by the Student-Newman-Keuls test, and the t test was used for two groups of samples. The standard for statistically significant differences between groups was p < 0.05.

[0220] In the examples of the present invention, the sequence information of SHMT2 siRNA is shown in Table 7.

[0221] Table 7. Sequence information of SHMT2 siRNA

[0222]

[0223] Example 1. High expression of SHMT2 in gastric cancer is associated with clinical malignant characteristics and poor prognosis of gastric cancer and is involved in maintaining the stemness characteristics of gastric cancer

[0224] In order to explore the relationship between SHMT2 expression and clinical pathological characteristics of gastric cancer, the present invention detected the expression of SHMT2 in gastric cancer tissue chips (containing 120 pairs of gastric cancer tissue samples) by in situ hybridization (ISH). The results showed that SHMT2 was highly expressed in gastric cancer tissues and was positively correlated with the patient's infiltration depth, lymph node metastasis, and grading and staging. For details, see Figure 1 and Figure 2 . Analysis of the patients' prognostic follow-up information revealed that high SHMT2 expression was closely associated with decreased overall survival rate of patients. Figure 3 -A. Our previous studies have found that SHMT2 is potentially involved in the maintenance of gastric cancer stem cells. In order to clarify the role of SHMT2 in the maintenance of gastric cancer stem cells, the present invention verified the expression of SHMT2 in gastric cancer cells and gastric cancer stem cells. The results showed that SHMT2 was significantly highly expressed in gastric cancer stem cells. For details, see Figure 3 -B. Further bioinformatics analysis revealed that the expression of SHMT2 in gastric cancer patients was positively correlated with the stemness-related factors MYC and SOX2. Figure 4 Then, we used gastric cancer tissue sections to analyze the expression correlation between SHMT2 and the stemness marker CD44 through IHC staining. The results showed that gastric cancer patients with higher SHMT2 expression also had high CD44 expression. Figure 5 The above results indicate that high expression of SHMT2 in gastric cancer is associated with the malignant characteristics and poor prognosis of gastric cancer, and is potentially involved in the maintenance of the stemness of gastric cancer stem cells.

[0225] In order to further clarify the effect of SHMT2 on the stemness of gastric cancer, we first constructed MGC-803 and BGC-823 cell line models with stable SHMT2 knockdown for subsequent experiments. Transwell experiments showed that the invasive ability of gastric cancer cells was significantly weakened after SHMT2 knockdown. Figure 6 . And the colony-forming ability of gastric cancer cells with SHMT2 knockdown is weakened, see Figure 7 . We further conducted a gastric cancer stem cell mammosphere formation experiment and found that compared with the mammospheres in the NC group, the mammospheres in the SHMT2 knockdown group were fewer in number and smaller in size. Figure 8-Figure 9 ). Next, the effect of SHMT2 knockdown on the expression of gastric tumor stemness marker proteins was further analyzed. Western blotting results showed that SHMT2 knockdown in gastric cancer cells could significantly reduce the expression of stemness markers c-MYC, CD44, and KLF4 proteins. Fig.10). The above results collectively indicate that knocking down SHMT2 can inhibit the stemness characteristics of GCSCs in vitro. Next, the present invention uses limiting dilution tumor formation experiments and nude mouse tumor formation experiments in vivo to explore whether SHMT2 has the same effect on maintaining the stemness characteristics of gastric cancer cells in vivo. The results in mice showed that knocking down SHMT2 can effectively inhibit the ability of GCSCs to form tumors in mice, as shown in Tables 8 and Fig.11 .

[0226] Table 8. Tumor formation ratio of the control group and SHMT2 knockdown group in mice detected by infinite dilution tumor formation experiment

[0227]

[0228] Note: Tumor size > 0.1 cm 2 ; n=7, (**, P<0.01).

[0229] The above results prove that high expression of SHMT2 is crucial for maintaining the stemness of gastric cancer stem cells, and knocking down SHMT2 can effectively inhibit the stemness characteristics of gastric cancer in vitro and in vivo.

[0230] Example 2. Overexpression of SHMT2 maintains the stemness of cancer stem cells by upregulating serine levels in GCSCs

[0231] In this example, amino acid metabolomics was used to detect the changes in serine / glycine in gastric cancer stem cells after SHMT2 knockdown. The results showed that SHMT2 knockdown in gastric cancer stem cells significantly reduced the level of cellular serine, while the level of glycine increased. For details, see Fig.12 Further, we supplemented serine in SHMT2-knockdown gastric cancer cells and found that exogenous addition of serine could effectively restore the weakened spheroidization ability of stem cells caused by SHMT2 knockdown. After serine supplementation, the number and volume of stem microspheres increased. For details, see Figure 13-14 Flow cytometry results also showed that after SHMT2 knockdown, the number of CD133+CD44+ gastric cancer stem cells was significantly reduced, while serine replenishment could restore the number of CD133+CD44+ gastric cancer stem cells. Fig.15 Consistent with this, in SHMT2 knockdown MGC-803 and BGC-823 cells, the expression of stemness marker proteins was significantly reduced, and exogenous addition of serine effectively restored the reduction of KLF4, CD44, and c-Myc caused by SHMT2 inhibition, as detailed in Fig.16 The above results indicate that high expression of SHMT2 can maintain the stemness characteristics of GCSCs by upregulating the level of serine in GCSCs.

[0232] Tumor stem cells have flexible metabolic activity, and their energy, biosynthesis and redox requirements are met through crosstalk of different metabolic pathways. One-carbon metabolism, as an important part of tumor crosstalk, not only affects amino acid metabolism (serine-glycine conversion), but also includes the folate cycle, methionine cycle and transsulfurization pathway. SHMT2, as a key enzyme in one-carbon metabolism, has recently been reported to be closely related to lipid metabolism. For example, SHMT2 can regulate hepatocyte lipid metabolism through glycine-mediated mTOR activation. Consistent with this, the present invention found changes in multiple lipid metabolic pathways in SHMT2-knocked-down gastric cancer stem cells, further confirming that SHMT2 potentially mediates the crosstalk between one-carbon metabolism and lipid metabolism. SHMT2-mediated serine / glycine reversible conversion is an important source of one-carbon units. Previous studies have shown that this metabolic pathway mainly proceeds in the direction of consuming serine, while the latest studies have found that SHMT2 is more inclined to consume glycine rather than produce glycine. The present invention also found that SHMT2 deficiency in gastric cancer stem cells led to increased glycine levels and a significant decrease in serine. Previous Nature articles have suggested that serine restriction can effectively induce the accumulation of anti-cancer lipid metabolites, thereby limiting spheroid formation and tumor growth. This study revealed from another perspective that SHMT2 deficiency-mediated serine reduction participates in the maintenance of tumor stem cell stemness by affecting membrane phospholipid remodeling, providing a new idea for tumor stem cell metabolic crosstalk.

[0233] Example 3. Synthesis and characterization of HA-Exo-si SHMT2 engineered exosomes

[0234] (1) Synthesis and characterization of HA-Exo-si SHMT2 engineered exosomes

[0235] In order to explore the targeted treatment strategy of gastric cancer stem cells, gastric cancer cell-derived exosomes were used to load SHMT2 siRNA and HA to improve its targeting. Fig.17 As shown, the specific steps are as follows:

[0236] 1) Gradient ultracentrifugation was used to extract exosomes from gastric cancer cells. First, the cell supernatant was collected, centrifuged at 300g for 10min, 1500g for 15min, and 3200g for 20min, and the supernatant was retained to remove the cell debris precipitate; then the supernatant was centrifuged continuously at 2000g for 30min at 4°C using an ultracentrifuge to separate the exosomes from large vesicles and subcellular structures. The supernatant was filtered through a 0.22um filter. The exosomes were collected by ultracentrifugation at 100000g for 70min at 4°C, and the exosomes sank to the bottom of the test tube. The exosomes were washed with sterile 1×PBS (calcium-free, magnesium-free, and phenol-free). The exosomes were collected by ultracentrifugation at 100000g for 70min at 4°C using an ultracentrifuge, and the exosomes sank to the bottom of the test tube. The precipitate was carefully resuspended in 200ul sterile 1×PBS to obtain exosomes.

[0237] 2) Cy5 fluorescently labeled si SHMT2 was added to the exosome solution obtained in step 1), and the exosomes and si SHMT2 were mixed in PBS at a ratio of 5:1, and the final concentration of EXOs in the mixture was 4 μg / ml. Ultrasonic treatment was performed to successfully load Cy5-si SHMT2. The ultrasound was set to an amplitude of 20%, 6 30-second on / off cycles, and a cooling time of 2 minutes between each cycle. Then, the solution was incubated at 37°C for 60 minutes to restore the exosome membrane. Finally, DSPE-PEG2000-HA (40 μg) was incubated with si SHMT2-loaded exosomes at 37°C for 48 hours, and then centrifuged at low speed (4000×g) to remove excess HA derivatives, thereby achieving HA coating of si SHMT2-loaded exosomes to obtain HA-Exo-si SHMT2 engineered exosomes.

[0238] Characterization of HA-Exo-si SHMT2 engineered exosomes. Transmission electron microscopy showed the morphology of HA-Exo-siSHMT2 exosomes, and dynamic light scattering (DLS) analysis was used to characterize HA-Exo-si SHMT2, which determined the average hydrodynamic size to be 162.8 ± 9.3 nm. Fig.18 At the same time, the Zeta potential of the collected exosomes (Exosome) and the assembled exosomes (HA-Exo-si SHMT2) was detected, where the potential of Exosome was -30.56±1.1mV, and the potential of HA-Exo-si SHMT2 was -35.24±2.17mV, indicating that the negative potential of the particles was enhanced after loading, which is beneficial to their circulation in the blood. For details, see Fig.19 -A. At the same time, the present invention characterized its seven-day particle size, see Fig.19-B, the results showed that the particle size of HA-Exo-si SHMT2 did not change significantly, and it had good stability. Western blotting results showed that both the prepared Exosomes and the engineered exosomes HA-Exo-si SHMT2 expressed characteristic exosomal membrane proteins ALIX and HSP70; in addition, HA was well expressed in HA-Exo-si SHMT2, proving that HA was successfully integrated into exosomes, see Fig.19 -C. CLAM shows significant colocalization of PKH67-labeled exosomes with Cy5-si SHMT2, see Fig. 20 , proving that SHMT2 siRNA was successfully loaded. The above results show that we have successfully constructed HA-Exo-si SHMT2 engineered exosomes, which have good stability.

[0239] (2) Uptake of HA-Exo-si SHMT2 by gastric cancer cells and gastric cancer stem cells

[0240] The present invention further explores the uptake of HA-Exo-si SHMT2 by gastric cancer cells and gastric cancer stem cells. HA-Exo-si SHMT2 was co-cultured with MGC-803. As the co-culture time increased, the uptake of HA-Exo-si SHMT2 by GC-803 gradually increased. Fig.21 -A. Similarly, after HA-Exo-si SHMT2 was co-cultured with MGC-803 / GCSC for 24 hours, the 3D confocal image showed that gastric cancer stem cells had a good uptake ability for HA-Exo-si SHMT2, see Fig.21 -B. To further verify the inhibition of SHMT2 by HA-Exo-si SHMT2 in gastric cancer cells and gastric cancer stem cells, the results of qRT-PCR and WB showed that HA-Exo-si SHMT2 intake could effectively inhibit the expression of SHMT2 in GC and GCSC. Fig. 22 -A~ Fig. 22 -B.

[0241] (3) Verification of the therapeutic effect of HA-Exo-si SHMT2

[0242] The therapeutic effect of HA-Exo-si SHMT2 was verified. When HA-Exo-si SHMT2 was exogenously added to MGC-803 and BGC-823 cells in vitro, the invasion and metastasis ability of gastric cancer cells was significantly reduced. For details, see Fig.23 , the clone-forming ability is weakened, see Fig.24 , the volume and number of gastric cancer stem cell microspheres decreased, see Fig.25 Similarly, the expression of stemness markers c-MYC, CD44, and KLF4 proteins was significantly reduced, see Fig.26 The above results show that HA-Exo-si SHMT2 can effectively inhibit the stemness characteristics of gastric cancer stem cells in vitro.

[0243] (4) In vivo therapeutic effect of HA-Exo-si SHMT2

[0244] To investigate the in vivo therapeutic effect of HA-Exo-si SHMT2, we injected HA-Exo-si SHMT2 (20ug / two days) into the tumor-bearing mouse model through the tail vein. After 14 days of treatment, we found that the tumor size was significantly inhibited. Fig. 27 There was no significant difference in the weight of mice between the treatment group and the non-treatment group. Fig.28 Next, IHC staining was used to detect the expression of c-MYC, CD44, KLF4, and SHMT2 in subcutaneous tumors. It was found that after HA-Exo-si SHMT2 treatment, the expression of SHMT2, CD44, and KLF4 in tumors was inhibited. Fig.29 . The above results indicate that HA-Exo-si SHMT2 can effectively inhibit the stemness characteristics and tumor progression of gastric cancer stem cells in vivo. In order to clarify the biosafety of HA-Exo-si SHMT2, HE staining was performed on the major organs of untreated and HA-Exo-si SHMT2-injected mice. The results showed that there was no significant difference in the heart, liver, spleen, lung, and kidney of mice. HA-Exo-siSHMT2 treatment did not cause damage to important organs in mice. For details, see Fig.30 At the same time, blood biochemical results showed that HA-Exo-siSHMT2 treatment did not lead to significant changes in biochemical indicators. The above results indicate that HA-Exo-si SHMT2 has good biocompatibility and therapeutic safety.

Claims

1. siRNA for the treatment of gastric cancer, It is characterized in that The siRNA is SHMT2 siRNA, the nucleotide sequence of the sense strand of the SHMT2 siRNA is shown as SEQ ID NO.1, and the nucleotide sequence of the antisense strand of the SHMT2 siRNA is shown as SEQ ID NO.

2.

2. Engineered exosomes for the treatment of gastric cancer, It is characterized in that The engineered exosomes include exosomes and SHMT2 siRNA encapsulated in the exosomes, the nucleotide sequence of the sense chain of the SHMT2 siRNA is shown in SEQ ID NO.1, and the nucleotide sequence of the Antisense chain of the SHMT2 siRNA is shown in SEQ ID NO.

2.

3. The engineered exosome according to claim 2, It is characterized in that The engineered exosomes also include hyaluronic acid modified on the surface of the exosomes.

4. The engineered exosome according to claim 3, It is characterized in that The hyaluronic acid is DSPE-PEG2000-HA.

5. The engineered exosome according to claim 2, It is characterized in that The exosomes are exosomes derived from gastric cancer cells.

6. The method for preparing the engineered exosomes according to any one of claims 2 to 5, It is characterized in that The steps include: (1) Gradient ultracentrifugation was used to extract exosomes from gastric cancer cells; (2) mixing SHMT2 siRNA with the exosomes obtained in step (1), sonicating, and incubating to obtain exosomes loaded with si SHMT2; (3) The siSHMT2-loaded exosomes obtained in step (2) were mixed with DSPE-PEG2000-HA and incubated to obtain HA-Exo-siSHMT2 engineered exosomes.

7. The preparation method according to claim 6, It is characterized in that In step (2), the SHMT2 siRNA is Cy5 fluorescently labeled si SHMT2.

8. The preparation method according to claim 6, It is characterized in that In step (2), the incubation is performed at 37±5°C for 60-120 minutes; and / or in step (3), the incubation is performed at 37±5°C for 36-60 hours.

9. Use of the siRNA according to claim 1 and / or the engineered exosomes according to any one of claims 2 to 5 in the preparation of a drug for treating gastric cancer.

10. The use according to claim 9, It is characterized in that The application includes any one of the following 1)-6): 1) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the stemness characteristics of gastric cancer stem cells; 2) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the invasion and metastasis ability of gastric cancer cells and / or gastric cancer stem cells; 3) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the cloning ability of gastric cancer cells and / or gastric cancer stem cells; 4) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting the expression of SHMT2, CD44, CD133, KLF4, and c-Myc in gastric cancer cells and / or gastric cancer stem cells; 5) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for inhibiting serine levels in gastric cancer stem cells; 6) Use of the siRNA and / or the engineered exosomes in the preparation of a drug for regulating one-carbon metabolism / lipid metabolism.